Webinar: Are you Ready for the Renaissance in Small Molecule Drug Discovery?
The webinar titled "Are you Ready for the Renaissance in Small Molecule Drug Discovery?" scheduled for February 2, 2023, features expert Haydn Boehm discussing challenges in small molecule drug discovery, emphasizing the importance of research collaboration, efficient data integration from multiple sources, and workflow optimization to reduce costs and accelerate finding better therapeutic candidates.
The process of small molecule discovery presents multiple challenges that impact time, cost, and risk for biotech professionals working toward therapeutic breakthroughs.
During this one-hour webinar, the current landscape of small and large molecule research is explored, including the friction points scientists may encounter in the small molecule drug discovery process.
Webinar Learning Objectives
- Understand why research collaboration is vitally important for all scientists working in this field.
- Learn how to get the most out of data from multiple sources by efficiently merging and managing all available data, regardless of origin.
- Discover ways to optimize your workflow according to specific needs, ultimately improving cycle times, reducing costs, and finding better candidates as quickly as possible.
Featured Speaker
Haydn Boehm
Haydn is dedicated to helping the life science and drug discovery industries harmonize their science and data, accelerating innovation to make the world a healthier, cleaner, and better place. He has 20 years of sales and marketing leadership experience in the life science industry, working with companies such as ThermoFisher Scientific, Johnson Matthey, and Merck KGaA’s Connected Lab Program. Haydn holds a PhD in Organic Chemistry from the University of Nottingham, UK, and resides on the Jurassic Coast in Devon, UK with his family.
Event Details
- Date: Feb 2, 2023
- Time: 11:00am CST
- Location: Online
Related
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
Lessons From The Past Year & My Opportunity to Spend More Time with You
Over the past year since the merger of Dotmatics and Insightful Science, the CEO has focused on building a strong leadership team and strategic acquisitions to enhance customer value, emphasizing the importance of a shared mission over just a shared vision to unify teams and drive purpose-driven work that supports scientific discovery, while acknowledging ongoing integration challenges and the benefits of their chosen M&A approach.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.